Synageva (Avigenics) addendum: What's notable about the $30M Synageva recently raised from the Baker Brothers is how much easier it was for Synageva to raise capital than it was for GTCB.
Despite the fact that GTCB has an approved drug (ATryn) based on transgenic mammals while no drug based on transgenic chickens is even close to regulatory approval, Synageva is clearly the more attractive investment.
Market Data 
Markets 
AI
